GNI Group

2160.TSE

19.33 USD

0.34

+1.79%

Overview

Last close

19.33 usd

Market cap

1.07B usd

52 week high

30.23 usd

52 week low

10.22 usd

Target price

27.56 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

6.2969

Price/Book Value

3.8167

Enterprise Value

781.16M usd

EV/Revenue

5.0505

EV/EBITDA

297.0235

Key financials

Revenue TTM

172.04M usd

Gross Profit TTM

128.15M usd

EBITDA TTM

-15.04M usd

Earnings per Share

-0.54 usd

Dividend

N/A usd

Total assets

535.03M usd

Net debt

-94.14M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.